Skip to main content
. 2013 Nov;33(21):4321–4333. doi: 10.1128/MCB.00776-13

Fig 1.

Fig 1

Loss of Dnmt1 delays MYC-induced T-cell lymphomagenesis. (A) Transgene schematic depicting the EμSRα-tTA; Teto-MYC; Teto-Cre; ROSA26EGFP/EGFP; Dnmt1flox/flox genetic setting used in these studies. tTA is expressed in ∼40% of cells and drives expression at the Teto promoter, resulting in transcription of the MYC oncogene and activating Cre-lox recombination to conditionally delete Dnmt1 and activate EGFP expression. (B) Kaplan-Meier survival curves of EμSRα-tTA; Teto-MYC; ROSA26EGFP/EGFP; Dnmt1flox/flox (F/F) and EμSRα-tTA; Teto-MYC; Teto-Cre; ROSA26EGFP/EGFP; Dnmt1flox/flox (−/−) mice. Median survival rates (MS), numbers of mice (n), and P values (log-rank test) are shown. (C) PCR-based analysis of deletion efficiency of the Dnmt1 conditional knockout allele in MYC; Dnmt1−/− tumors. F and KO indicate DNA fragments derived from the floxed and knockout alleles, respectively. Dnmt1flox/flox and Dnmt1flox/− genomic DNAs served as controls. NC indicates negative control (no DNA). (D) Immunoblot analysis of Dnmt1 expression in normal thymocytes (Th) and in MYC; Dnmt1flox/flox and MYC; Dnmt1−/− lymphomas. γ-Tubulin served as a loading control. (E) PCR-based analysis of deletion efficiency of the Dnmt1 conditional knockout allele in cellular clones from MYC; Dnmt1−/− tumors. The top and bottom panels represent two tumors with 10 clones each. F and KO indicate floxed and knockout alleles, respectively. Dnmt1flox/flox and Dnmt1flox/− genomic DNAs served as controls. NC indicates negative control (no DNA). (F) Immunoblot analysis of Dnmt3a and Dnmt3b expression in normal thymocytes (Th) and in MYC; Dnmt1flox/flox and MYC; Dnmt1−/− lymphomas. (G) Representative examples of FACS analysis from immunophenotyping of MYC; Dnmt1−/− tumors using anti-CD4 and anti-CD8 antibodies. Examples of CD4 single-positive and CD4/CD8 double-positive tumors are shown. (H) Summary of immunophenotypes for CD4 single-positive and CD4/CD8 double-positive tumors as determined by FACS analysis using CD4 and CD8 expression in MYC; Dnmt1flox/flox and MYC; Dnmt1−/− lymphomas.